<DOC>
	<DOCNO>NCT00404404</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , ABI-007 , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some find tumor cell kill carry tumor-killing substance . Others interfere ability tumor cell grow spread . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving ABI-007 together bevacizumab may kill tumor cell . PURPOSE : This phase II study well give ABI-007 together bevacizumab work treat woman recurrent metastatic breast cancer .</brief_summary>
	<brief_title>ABI-007 Bevacizumab Treating Women With Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine activity paclitaxel albumin-stabilized nanoparticle formulation ( ABI-007 ; Abraxane^® ) bevacizumab , term progression-free survival response rate , woman recurrent metastatic breast cancer . Secondary - Determine toxicity profile regimen patient . - Determine feasibility regimen patient . OUTLINE : This open-label , pilot study . Patients receive paclitaxel albumin-stabilized nanoparticle formulation ( ABI-007 ; Abraxane^® ) IV 30 minute day 1 , 8 , 15 bevacizumab IV 30-90 minute day 1 15 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year every 6 month 3 year . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm invasive breast cancer Recurrent metastatic disease OR locally recurrent disease amenable resection curative intent Measurable nonmeasurable disease No CNS metastases CT scan MRI No HER2neupositive tumor Hormone receptor status specify PATIENT CHARACTERISTICS : Female Menopausal status specify Performance status 01 Absolute neutrophil count ≥ 1,500/mm³ Platelet count &gt; 100,000/mm³ Creatinine &lt; 2.0 mg/dL Bilirubin normal AST ≤ 2 time upper limit normal ( ULN ) ( 5 time ULN know liver involvement ) Urine protein : creatinine ratio &lt; 1.0 OR proteinuria &lt; 2+ urine dipstick OR ≤ 1 g protein 24hour urine collection No peripheral neuropathy &gt; grade 1 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except carcinoma situ cervix , melanoma situ , basal cell carcinoma skin No inadequately control hypertension , define systolic blood pressure ( BP ) &gt; 150 mm Hg and/or diastolic BP &gt; 100 mm Hg antihypertensive medication No prior hypertensive crisis hypertensive encephalopathy No New York Heart Association class IIIV congestive heart failure No myocardial infarction unstable angina within past 6 month No stroke transient ischemic attack within past 6 month No significant vascular disease ( e.g. , aortic aneurysm aortic dissection ) No symptomatic peripheral vascular disease No evidence bleed diathesis coagulopathy No significant traumatic injury within past 28 day No abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month No serious , nonhealing wound , ulcer , bone fracture No known hypersensitivity component bevacizumab PRIOR CONCURRENT THERAPY : No prior paclitaxel albuminstabilized nanoparticle formulation ( ABI007 ; Abraxane^® ) bevacizumab No prior chemotherapy metastatic disease Prior hormonal therapy metastatic disease allow At least 4 week since prior therapy cancer More 12 month since prior adjuvant chemotherapy , include use taxane More 28 day since prior major surgery open biopsy More 7 day since prior core biopsy minor surgery ( exclude placement vascular access device ) No concurrent major surgery No concurrent therapy breast cancer Concurrent bisphosphonates allow bone involvement No concurrent prophylactic granulocyte colonystimulating factor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>